In Re Vitamin Cases

2 Cal. Rptr. 3d 358, 110 Cal. App. 4th 1041
California Court of Appeal·Decided August 20, 2003·No. A098354·Published·Cited by 40 cases

Opinion

Opinion

HAERLE, J.

I. INTRODUCTION

This appeal challenges the attorney fees and costs awarded class counsel following settlement of numerous class action complaints brought against various manufacturers of vitamin products. Sandra Norris, the single objecting class member, raises many issues with respect to the award of attorney fees, but the main thrust of her appeal challenges the lodestar figure requested by class counsel, the multiplier that was applied to that figure, and the size of the resulting award as a percentage of the settlement fund. We reverse and remand with directions to the trial court to provide a more complete explanation for the award of fees and costs.

n. FACTUAL AND PROCEDURAL BACKGROUND

In 1998, the first antitrust class action lawsuit brought on behalf of direct purchasers of vitamins was filed in federal district court. (In re Vitamins Antitrust Litigation (D.D.C. 2002) 209 F.R.D. 251, 254.) Ultimately, approximately 49 federal cases were filed and coordinated in a multidistrict litigation proceeding in the federal district court for the District of Columbia (MDL litigation). (In re Vitamins Antitrust Litigation (D.D.C. 1999) 1999 U.S. Dist. LEXIS 21963, 1999 WL 1335318, *1.) That coordinated action alleged a conspiracy to fix the prices of the following vitamins sold in bulk; A, B1, B2, B3, B4 (also known as choline chloride), B5, B6, B12, C, E, H, beta carotene, astaxanthin, and canthaxanthin. (Cf. In re Vitamins Antitrust Litigation, supra, 209 F.R.D. at p. 254 & fn. 2.)

*1044 In July 1998, a similar action on behalf of indirect purchasers of bulk vitamin products was filed in Yolo County, California. Other indirect purchaser actions were filed in various states across the country.

Somewhere in this time period, the United States Department of Justice (DOJ), also suspecting that price-fixing had occurred, filed a criminal information alleging that Lonza A.G. (Lonza) (not a party to this appeal) had fixed the price of vitamin B3 in violation of section 1 of the Sherman Act (15 U.S.C. § 1). On March 1, 1999, Lonza pleaded guilty to those charges. On March 2, 1999, executives and officers of Chinook, Inc., and Du Coa, L.P. (also not parties to this appeal) pleaded guilty to similar charges with respect to sales of vitamin B4.

Six days later, on March 8, 1999, Saveri & Saveri P.C. (the Saveri firm) filed a class action in San Francisco Superior Court on behalf of indirect purchasers. On March 16, 1999, Lieff, Cabraser, Heimann & Bernstein, LLP (LCHB) filed a similar action in the same court. Apparently, a third action was also filed in San Francisco Superior Court because, on April 8, 1999, the trial court filed a pretrial order establishing the procedure for litigation in those three cases. Pursuant to that order, LCHB and the Saveri firm were to serve as plaintiffs’ co-liaison counsel. Those two firms, along with the Mogin Law Firm and Bainbridge & Strauss, were to serve as the executive committee, and the executive committee along with eight additional law firms were to comprise the steering committee.

Later, the trial court added four additional firms to the executive committee and 17 additional firms to the steering committee. By the time the case settled, two more firms, for a total of 10 firms, had been added to the executive committee. By that time the steering committee, which admittedly never met, was composed of 57 law firms. Thus, at the time the settlement agreement at issue here was executed, a total of 67 law firms were involved in the litigation and listed as such in a schedule attached to that agreement.

On May 14, 1999, the trial court granted a petition for coordination of the-three San Francisco Superior Court actions and the single action filed in Yolo County. On May 21, 1999, a first consolidated amended complaint was filed in San Francisco Superior Court. The complaint described the plaintiff class as Californians who indirectly purchased vitamins, vitamin premixes, and/or other vitamin products from any of the named manufacturers, for use, but not for resale, at any time during the period January 1, 1988 through the late 1990’s. The complaint contended that the defendants, manufacturers of “raw vitamins, ... vitamin premixes, and other bulk vitamin products for bulk sales,” committed price-fixing in violation of both the Cartwright Act (Bus. & Prof. Code, § 16700 et seq.) and the Unfair Competition Act (Bus. & Prof. Code, § 17200 et seq.).

*1045 On May 20 and September 9, 1999, five of the seven defendants who are parties to the settlement agreement at issue in this case entered guilty pleas in the DOJ’s criminal action in the federal district court for the District of Columbia with respect to “the sales of certain vitamins.” 1

On July 27, 1999, eleven additional cases were coordinated in San Francisco Superior Court. On August 18, 1999, three more cases were added to the coordinated proceeding, on August 26, 1999, eleven more cases, and on October 13, 1999, five more cases, were added. The total number of private antitrust class actions thus totaled 34. 2

On November 23, 1999, plaintiffs in the federal MDL litigation filed a motion for preliminary approval of a settlement that they had reached with some of the defendants in that action. (See In re Vitamins Antitrust Litigation, supra, 1999 U.S. Dist. LEXIS 21963, 1999 WL 1335318, *1.) The defendants who settled in that case included the same defendants who have settled in this action. (See ibid.) On March 31, 2000, the federal district court granted final approval of the settlement agreement. (See In re Vitamins Antitrust Litigation (D.D.C. 2000) 2000 U.S. Dist. LEXIS 8931, 2000 WL 1737867, *1.)

On October 31, 2000, the California Attorney General, acting on behalf of the People of the State of California, filed an action in San Francisco Superior Court that contained allegations similar to those made in the other actions coordinated in that court. The Attorney General’s complaint named only seven of the defendants named in the coordinated proceeding. On November 29, 2000, the Attorney General’s lawsuit was added to the state court coordinated proceeding.

On August 29, 2001, the class representatives in the coordinated proceeding and the People filed a motion for preliminary approval of class action settlement with the seven defendants named in the Attorney General’s complaint: BASF Corp., Daiichi Pharmaceutical Co., Ltd., Eisai Co., Ltd., Aventis Animal Nutrition S.A. (formerly Rhone-Poulenc Animal Nutrition, S.A.), Hofifman-La Roche, Inc., Roche Vitamins, Inc., and Takeda Chemical Industries, Ltd. (collectively, Settling Defendants). The settlement agreement *1046 identified 36 separate state actions that it would resolve. 3

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Vitamin Cases, 2 Cal. Rptr. 3d 358, 110 Cal. App. 4th 1041 (Cal. Ct. App. 2003).

2 Cal. Rptr. 3d 358 (In Re Vitamin Cases) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Sarkany v. West CA1/1
California Court of Appeal, 2026
Perry v. Stuart
California Court of Appeal, 2025
Zaharin v. FCA Corp.
N.D. California, 2025
Konkov v. Doubson CA6
California Court of Appeal, 2024
G.G. v. B.E. CA2/4
California Court of Appeal, 2023
Sierra Club v. County of San Diego CA4/1
California Court of Appeal, 2022
Lave v. Charter Communications CA4/1
California Court of Appeal, 2020
Wheeler v. King Digital Entertainment PLC CA1/5
California Court of Appeal, 2020
Mikhaeilpoor v. BMW of North America, LLC
California Court of Appeal, 2020
Sanchez v. Frito-Lay, Inc.
E.D. California, 2019
Amaro v. Gerawan Farming, Inc.
E.D. California, 2019